JPM大会落幕，中国创新药再成全球焦点！港股通创新药ETF(159570)深度回调2.5%，资金快速涌入，近5日狂揽超10亿元！

Group 1 - The Hong Kong Innovation Drug ETF (159570) has experienced a 2.5% decline for three consecutive days, with a trading volume exceeding 800 million yuan, and has attracted over 1 billion yuan in the last five days [1][3] - As of January 16, the latest scale of the Hong Kong Innovation Drug ETF (159570) has surpassed 26.2 billion yuan, leading its peers in the same category [1] - The majority of the weighted stocks in the ETF's index have shown negative performance, with notable declines including Kelun-Bio down over 5%, Innovent Biologics and Hansoh Pharmaceutical down over 4%, and others down over 3% [3][4] Group 2 - The 44th JPMorgan Healthcare Conference took place from January 12 to 15, featuring several Chinese innovative pharmaceutical companies, including WuXi AppTec and BeiGene, among others [5] - Huatai Securities noted that the JPM conference and the upcoming annual report cycle in February could serve as catalysts for the market, which is currently at a relative bottom, with expectations for new highs in the innovative drug sector [5] - Zhongtai Securities highlighted multiple catalysts in the pharmaceutical sector, including significant data disclosures from multinational corporations and various business development deals, indicating a positive outlook for the innovative drug industry [5][6] Group 3 - The 2026 JPMorgan Conference is expected to showcase Chinese innovative drugs as a global highlight, with over 20 Chinese pharmaceutical companies participating [7] - Companies like HengRui are projected to see a 25%+ growth in innovative drug revenue by 2026, with several key drugs and indications expected to be approved in the next two years [7] - Notable developments include RC148's licensing deal worth up to 5.6 billion USD between Rongchang Bio and AbbVie, and various clinical trial advancements from companies like Summit Therapeutics and Eifang Bio [8]